Abdominal Cancer Surgery

Medical Team


Peritoneal Neoplastic Disease program

The CHI Health Creighton University Medical Center Peritoneal Neoplastic Disease program in Omaha was established in 2002 by CHI Health oncology surgeon Dr. Brian Loggie. In the early 90s, during his tenure at Wake Forest University Baptist Medical Center, Dr. Loggie’s frustration with the lack of treatment options for peritoneal cancer led him to develop a revolutionary treatment that provides hope for patients with peritoneal cancer, including those in the late stages.

Dr. Loggie's expertise is in surgical oncology and the management and treatment of rare cancers has earned him a national and international reputation for his expertise in the field. Patients from all 50 states and several countries have been treated through the Peritoneal Neoplastic Disease program.

Cancers we treat

The Peritoneal Neoplastic Disease program staff treats individuals who have rare diseases as malignant peritoneal mesothelioma, cutaneous malignant melanoma, peritoneal carcinomatosis and malignant ascites, abdominopelvic and retroperitoneal sarcomas, pseudomyxoma peritonei, and management of complex primary, recurrent solid tumors and appendix neoplasms. Patients with more common underlying diseases such as colon cancer or ovarian cancer also are treated through the program. 

Cytoreductive surgery and heated chemotherapy

Dr. Loggie pioneered the use of intraperitoneal heated chemotherapy (IPHC or HIPEC) and cytoreductive surgery. After cytoreductive surgery to remove all visible cancer tumors, during the same procedure the abdominal cavity is bathed for two hours with a chemotherapy agent which is heated to 106 degrees Fahrenheit. This process kills cancer cells that are not visible. Due to the complexity of the combined therapy of cytoreductive surgery and HIPEC, few surgeons are appropriately trained and experienced to offer this treatment option.  

This two-pronged treatment option and has achieved better patient outcomes than either procedure alone. Data show patients undergoing this treatment live longer and have a better quality of life. The choice of chemotherapy drug also has played a significant role. In a study of mesothelioma patients conducted by Dr. Loggie, he concluded that Carboplatin is the preferred IPHC /HIPEC agent.

For more information

For more information about the Peritoneal Neoplastic Disease program at Creighton University Medical Center, please call 402-717-0090 or email info@alegent.org.